NCT07457138Recruiting
Lombard Cohort of Brain Health Services
Source: ClinicalTrials.gov · Last updated 17 Mar 2026
Brief summary (registry, in English)
The goal of this multicenter prospective observational cohort study is to better understand the clinical, neuropsychological, and biological characteristics of individuals attending Brain Health Services (BHS) in the Lombardy region. The study focuses on adults with subjective cognitive decline (SCD), functional cognitive disorder (FCD), or "well worried" individuals without objective cognitive impairment. The main questions it aims to answer are: * What clinical, cognitive, and biological differences exist between individuals who are positive versus negative for Alzheimer's disease (AD) plasma biomarkers (p-tau217) at baseline? * What factors predict positivity to AD biomarkers at baseline? * How does communication of biomarker results (risk disclosure) affect psychological well-being shortly after receiving results? * What factors predict longitudinal changes in AD biomarkers over 5 years? * Do baseline biomarkers predict the development of mild cognitive impairment (MCI) or dementia during follow-up? Participants will: * Undergo standard clinical evaluation at their local BHS * Provide blood samples for plasma biomarker analysis (e.g., p-tau217, GFAP, NfL, ApoE) * Undergo neuropsychological testing and cognitive screening * Complete questionnaires assessing psychological impact and risk perception (before and after biomarker disclosure) * Undergo additional center-specific procedures when clinically indicated (e.g., MRI, lumbar puncture, polysomnography) * Be followed annually for 5 years The study plans to enroll approximately 1000 participants across multiple BHS in Lombardy and will follow them for a total duration of 7 years. The results will help clarify the role of biomarkers in early cognitive complaints and support the development of preventive strategies within BHS.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 2 Mar 2026
- Start date
- Feb 2026
- Primary completion date
- Feb 2028
- Lead sponsor
- University of Milano Bicocca
- Diseases
- Alzheimer disease
- NCT number
- NCT07457138
What you commit to
- Study type: Observational
- Planned participants: 1000
- From Feb 2026 to the primary completion date, Feb 2028
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosis of mild cognitive impairment or dementia at baseline visit
Other
- Enrollment in another interventional study with an expected effect on cognition
- Pregnancy or breastfeeding
Who the study is looking for
- Adults (≥18 years)
- Diagnosis of SCD, FCD, or "well worried" individuals without objective cognitive impairment
- Evaluation at one of the Lombardy BHS
- Ability to provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Villa Beretta Rehabilitation Center Coordinator of this site? Confirm its status | Costa Masnaga | Italy | Recruiting |
| IRCCS Don Gnocchi Coordinator of this site? Confirm its status | Milan | Italy | Not yet recruiting |
| IRCCS Auxologico Coordinator of this site? Confirm its status | Milan | Italy | Not yet recruiting |
| Fondazione IRCCS San Gerardo dei Tintori Coordinator of this site? Confirm its status | Monza | Italy | Recruiting |
| IRCCS Policlinico San Donato Coordinator of this site? Confirm its status | San Donato Milanese | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.